RYTM Q2 2024 Earnings — Rhythm Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RYTMRhythm Pharmaceuticals, Inc.

$6B

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$29M+51.3% YoY

Gross Profit

$26M89.9% margin

Operating Income

-$40M-139.2% margin

Net Income

-$32M-110.9% margin

EPS (Diluted)

$-0.53

QoQ Revenue Growth

+12.0%

Cash Flow

Operating Cash Flow

-$29M

Free Cash Flow

-$29M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$382M

Total Liabilities

$202M

Stockholders' Equity

$179M

Cash & Equivalents

$162M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$29M	$19M	+51.3%
Gross Profit	$26M	$17M	+53.8%
Operating Income	-$40M	-$47M	+13.1%
Net Income	-$32M	-$47M	+30.9%

Revenue Segments

Product

$29M100%